secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quanterix Corp (QTRX)
CIK:        0001503274
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001104659-22-115930
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quanterix Q3 net loss $35.1M; takes $20.6M in impairment and restructuring charges
--------------------------------------------------------------------------------

- Revenue $26.6M flat YoY excluding RADx, up 13% QoQ; pro-forma gross margin 35.0% (down 1470 bps YoY, up 670 bps QoQ).
- Net loss $35.1M ($0.95/share) vs $15.7M loss a year ago; operating loss $36.6M.
- Recorded $8.2M goodwill impairment, $8.7M long-lived asset impairment, $3.4M restructuring costs in Q3.
- Business highlights: BioHermes pTau-181 trial nearing completion for FDA clearance; ADDF-funded Alzheimer's plasma test on track.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503274/000110465922115930/0001104659-22-115930-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503274/000110465922115930/tm2229964d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-115930

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer